Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin

Coadministration of Dabigatran Etexilate and Atorvastatin

(2013) Joachim Stangier et al.   American Journal of Cardiovascular Drugs

Practical aspects of the oral new anticoagulants

(2011) Thomas G. DeLoughery   AMERICAN JOURNAL OF HEMATOLOGY

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

(2011) Ola Dahl et al.   THROMBOSIS AND HAEMOSTASIS

Vitamin K Antagonists – Current Concepts and Challenges

(2011) Hayan Moualla et al.   THROMBOSIS RESEARCH

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren

(2010) Tuija Tapaninen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

(2010) Mike Ufer   THROMBOSIS AND HAEMOSTASIS

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors

(2008) A. Gupta et al.   DRUG METABOLISM AND DISPOSITION